2016
Safety and efficacy of sofosbuvir‐containing regimens in hepatitis C‐infected patients with impaired renal function
Abstract: Sustained viral clearance was achieved in 83% of patients with renal impairment (eGFR ≤45 ml/min/1.73 m(2) ) treated with SOF-containing regimens. However, these patients had higher rates of anaemia, worsening renal dysfunction and serious adverse events regardless of use of RBV. Patient with renal impairment require close monitoring and should be treated by providers extensively experienced with SOF-containing regimens.
Search citation statements
Paper Sections
Select...
219
69
35
7
Citation Types
17
241
5
13
Year Published
2014
2025
Publication Types
Select...
281
10
7
2
Relationship
9
291
Authors
Journals
Cited by 300 publications
(276 citation statements)
References 19 publications
17
241
5
13
“…In contrast, the study performed by Saxena et al. demonstrated that chronic HCV patients with baseline GFR <45 mL/min/1.73 m 2 presented worsening in renal function after DAA therapy in a large multicentre retrospective cohort . In our study, proteinuria and albuminuria slightly decreased levels after treatment; however, no statistic differences were observed.…”
Section: Discussioncontrasting
confidence: 95%
“…In contrast, the study performed by Saxena et al. demonstrated that chronic HCV patients with baseline GFR <45 mL/min/1.73 m 2 presented worsening in renal function after DAA therapy in a large multicentre retrospective cohort . In our study, proteinuria and albuminuria slightly decreased levels after treatment; however, no statistic differences were observed.…”
Section: Discussioncontrasting
confidence: 95%
“…In our study, the rate of treatment success was high (98.9%) and all patients who presented significant renal impairment reached SVR. Previous reports confirmed high rates of treatment success for patients with renal disease . In addition, our results also follow in accordance to those studies which observed low rates of dose adjustments or adverse effects due to renal dysfunction during DAA therapy, where no evidence of treatment discontinuation was observed …”
Section: Discussionsupporting
confidence: 93%
“…In our study, overall SVR rates (96%) were comparable to those reported in registration trials [2,3] and real-life studies [5,6,[8][9][10][11][12][13], and were independent of baseline renal function, as previously reported [11,12,19,33]. Interestingly, the highest SVR rates were achieved by those treated with SOF-free (p = 0.0003) and RBV-free (p = 0.0017) combinations.…”
Section: Discussionsupporting
confidence: 89%
“…This is similar to findings from the HCV-TARGET study, with slightly higher early discontinuation rates in patients with eGFR <45 mL/min (4.1 vs. 2.5%, p = nonsignificant) [31]. The early discontinuation rates reported in this study are higher than those reported in previous case series and clinical trial results.…”
Section: Discussionsupporting
confidence: 88%
“…In this study, patients with CKD were slightly more likely to discontinue treatment early than non-CKD patients (15.6 vs. 12.0%); however, the results were not significant. This is similar to findings from the HCV-TARGET study, with slightly higher early discontinuation rates in patients with eGFR <45 mL/min (4.1 vs. 2.5%, p = nonsignificant) [ 31 ]. The early discontinuation rates reported in this study are higher than those reported in previous case series and clinical trial results.…”
Section: Discussionsupporting
confidence: 87%
